Navigation Links
Arpida Presents Preclinical Data on AR-2474 at ICAAC
Date:9/21/2007

REINACH and BASEL, Switzerland, September 21 /PRNewswire-FirstCall/ -- Arpida Ltd (SWX: ARPN) presented several preclinical studies on its novel topical antibiotic AR-2474 at the 47th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago. ICAAC is a major scientific conference where thousands of scientists and clinicians from all over the world gather to discuss the latest developments in the field of infectious diseases.

AR-2474 is a novel synthetic antibacterial currently under development for topical indications including treatment of infections and prevention of transmission of the "superbug" MRSA. AR-2474 is a diphenyl urea with unique properties.

F1-2100: The topical activity and potency of AR-2474 was compared with the gold standard mupirocin (Bactroban(R)) in two preclinical models of MRSA infection of the skin and of nasal decolonisation. In both models, a preliminary topical formulation of AR-2474 was demonstrated to be as efficacious as mupirocin.

F1-2094, F1-2095, F1-2096, F1-2097, F1-2100A: The in vitro microbiological activity of AR-2474 and of other compounds of the class was assessed in-house and by leading laboratories against large panels of clinical isolates. AR-2474 showed potent activity against methicillin susceptible and resistant staphylococci including nosocomial and community S. aureus isolates. Importantly, AR-2474 exhibits no cross-resistance with other classes of currently used topical treatments. The compound also exhibited potent activity against Group A and B streptococci, enterococci, pneumococci and other important pathogens responsible for causing infections of the skin, eye and mouth.

F1-2099: AR-2474 demonstrated little or no propensity for resistance development. No resistant mutants to AR-2474 could be selected using different methodologies.

F1-2098: The data showed that AR-2474 is bactericidal, exhibits a post antibiotic effect and shows no antagonism wi
'/>"/>

SOURCE Arpida Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NimbleGen presents new tech for comparing microbe DNA
2. Wisconsin Technology Network presents symposium on saving lives by the use of Information Technology
3. Thieme Presents Unique Technology Angle at Gov.s Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... SAO PAULO , June 2, 2015   ... leader in biosimilars, today announced that its partner, Celltrion – ... ANVISA – the National Health Surveillance Agency in ... first biosimilar monoclonal antibody approved for use in ... by Hospira. Hospira also markets and sells biosimilar infliximab ...
(Date:6/2/2015)... LOUIS , June 2, 2015   ... Life Science and Technology company, announced today it ... Science to launch genetically engineered human neural ... advance the research of neurological diseases. These new ... provide unique and versatile tools for the study ...
(Date:6/2/2015)... June 02, 2015 Through rare discovery ... Yancy Corporation is enabling World Scientists to ... and biological sample, displaying the full nature (position, shape, ... atoms. , Jeff Porter, Co-Founder of the Yancy Corporation, ... that – rare. They come once in a lifetime, ...
(Date:6/1/2015)... June 1, 2015  Turing Pharmaceuticals AG announced that ... Salinas , MD, MSc,  has joined the company ... Dr. Salinas, who holds a medical degree as ... record of significant accomplishments in the pharmaceutical industry, ... Dr. Salinas has played a leadership role in ...
Breaking Biology Technology:ANVISA Approves First Infliximab Biosimilar in Brazil 2ANVISA Approves First Infliximab Biosimilar in Brazil 3ANVISA Approves First Infliximab Biosimilar in Brazil 4ANVISA Approves First Infliximab Biosimilar in Brazil 5Sigma-Aldrich to Launch XCell Science Genetically Engineered iPSC-Derived Neural Disease Cells 2Sigma-Aldrich to Launch XCell Science Genetically Engineered iPSC-Derived Neural Disease Cells 3Scientists Eying Rare Discovery Of New Physics & Light Microscope Technology 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3
... CRANBURY, N.J., Aug. 12 Palatin Technologies, Inc. (NYSE ... of a Phase 1 clinical trial of subcutaneously administered ... male erectile dysfunction (ED) and female sexual dysfunction (FSD). ... blood plasma levels can be obtained without blood pressure ...
... Health care jobs continue ... industry remains at 20,000 monthly, and health care has one of the the lowest unemployment rates ... feeling the economic pinch more and more. , ... (Vocus) August 12, 2009 -- There is a dichotomy between simultaneous job creation and job ...
... Scientists drew fittingly from Roman mythology when they named ... Janus, who is usually depicted as having two faces ... been fascinated by the tantalizing possibilities of these particles ... and many other devices. However, realizing these applications requires ...
Cached Biology Technology:Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration 2Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration 3Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration 4The MedZilla Report for July, 2009 - Health Care Creates 20,000 More Jobs As Economy Hits Insurers 2The MedZilla Report for July, 2009 - Health Care Creates 20,000 More Jobs As Economy Hits Insurers 3The MedZilla Report for July, 2009 - Health Care Creates 20,000 More Jobs As Economy Hits Insurers 4Capping a two-faced particle gives duke engineers complete control 2
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, reminds investors and media that  Mr. ...  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of nine ... Global Fraud: Where is the Trust in Cyberspace? ...
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... Although Antarctic krill (Euphausia superba) are one of the ... their life cycle have remained murky. , Understanding krill ... birds, and marine mammals, yet they are vulnerable to ... issue of BioScience, the monthly journal of the American ...
... Division of Cellegy Pharmaceuticals, Inc. today announced a non-exclusive ... the prevention of HIV and other sexually transmitted diseases. ... the agreement are in various stages of development and ... Savvy, which is currently in Phase III clinical trials ...
... five percent of deaths from SIDS (sudden infant death syndrome) ... gene and half of those deaths result from a common ... abnormal heart rhythm during times of environmental stress, a research ... February 2006 issue of the Journal of Clinical Investigation. ...
Cached Biology News:New licensing agreement to maximize AIDS drug development 2Gene variation increases SIDS risk in African Americans 2Gene variation increases SIDS risk in African Americans 3
Human alpha-1-antitrypsin. No cross-reactivity with alpha-1-acid glycoprotein, serum albumin or other serum proteins....
Phosphorylcholine hapten is conjugated to BSA protein by use of p-diazonium phenylphosphorylcholine....
Viral CMV UL146/vCXC1 Biotinylated Affinity Purified PAb...
Blue Standard is 3-cyano-7-hydroxycoumarin....
Biology Products: